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Abstract: Neurological disorders such as stroke, Alzheimer’s and Parkinson’s diseases are associated
with high morbidity and mortality, and few or no effective options are available for their treatment.
These disorders share common pathological characteristics like the induction of oxidative stress,
abnormal protein aggregation, perturbed Ca2+ homeostasis, excitotoxicity, inflammation and
apoptosis. A large body of evidence supports the beneficial effects of the Mediterranean diet in
preventing neurodegeneration. As the Mediterranean diet is characterized by a high consumption
of extra-virgin olive oil it has been hypothesized that olive oil, and in particular its phenols, could
be responsible for the beneficial effect of the Mediterranean diet. This review provides an updated
vision of the beneficial properties of olive oil and olive oil phenols in preventing/counteracting both
acute and chronic neurodegenerative diseases.
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1. Introduction
Neurodegenerative disorders, both chronic, such as Alzheimer’s disease (AD) and Parkinson’s
disease (PD), and acute such as stroke and spinal cord injury (SCI), are associated with high morbidity
and mortality, and few or no effective options are available for their treatment [1,2]. These diseases
represent a primary health problem especially in the aging population [3]. For example, AD is the most
common form of dementia and affects around 27 million people worldwide with incidence increasing
from 1% between the ages of 60 and 70 to 6–8% by 85 years [4,5]. PD, the second most prevalent
neurodegenerative disease, affects 1% to 2% of the population above the age of 65 [6,7]. In 2005, stroke
was responsible for 5.7 million (16.6%) deaths [7] and SCI affects 1.3 million North Americans [8].
There is a strict correlation between acute and chronic brain diseases as acute brain injuries are risk
factors associated with chronic neurodegenerative diseases such as AD and PD [9–12]. These disorders
share common pathological characteristics such as the induction of oxidative stress, abnormal protein
aggregation, perturbed Ca2+ homeostasis, excitotoxicity, inflammation and apoptosis [13,14]. In recent
years, many studies have been focused on natural phytocomponents present in food as important
bioactive molecules against age-related chronic diseases as neurodegenerative diseases [15–20] and a
large body of evidence supports the beneficial effects of the Mediterranean diet (MD) in preventing
neurodegeneration, possibly due to its richness in phenols [21–25]. Phytochemicals exert different
biological activity, including antioxidant, antiallergic, anti-inflammatory, antiviral, antiproliferative,
and anticarcinogenic effects [26–28]. MD is characterized by a daily consumption of extra-virgin olive
oil in amounts ranging from 25 to 50 g/day [29–31], so it has been hypothesized that olive oil phenols
could in part be responsible for the beneficial effect of the MD [32,33].
The olive tree (Olea europaea) synthesizes different phenols, found mainly in the leaves and
drupes, used as defense against microbial and fungal invasion as well as to give leaves and drupes an
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unpleasant taste that discourages leaf-eating insects [34]. Natural phenols have been demonstrated
to have many biological activities: they are able to modulate cell redox state [35] through direct
action on enzymes, proteins, receptors, and different signaling pathways [36,37], as well as to
interfere with biochemical homeostasis [38,39]. It has been shown that some of these effects are
related to epigenetic modifications of the chromatin [40,41]. This review provides an updated vision
of the beneficial properties of olive oil and olive oil phytochemicals (phenols and triterpenes) in
preventing/counteracting both acute and chronic neurodegenerative diseases.
2. Methods
The Pubmed database was searched up to September 2017 using the keywords “Alzheimer’s
disease”, “Parkinson’s disease”, “traumatic brain injury”, “spinal cord injury”, “stroke”, “amyotrophic
lateral sclerosis”, “multiple sclerosis”, “ischemic brain injury”, “brain ipoxia”, “Huntington’s disease”,
“oxidative stress”, “autophagy”, “proteasome” in combination with “olive oil”, “oleocanthal”,
“tyrosol”, “hydroxytyrosol”, “oleuropein”. We also examined the reference lists of the retrieved articles.
Criteria for inclusion in the review were as follows: (1) English language full-length publication in
a peer-reviewed journal; (2) articles that directly addressed the topic of olive oil and its phenols.
The ClinicalTrials.gov database was investigated using the same search criteria.
3. Olive Oil Phenols
More than 200 different chemical compounds have been detected in olive oil including sterols,
carotenoids, triterpenic alcohols and phenolic compounds. Phenolic compounds are also the main
antioxidants found in virgin olive oil, which contains both hydrophilic and lipophilic phenols [42].
The main phenolic subclasses present in olive oil are phenolic alcohols, phenolic acids, flavonoids,
lignans, and secoiridoids [43,44]. In Figure 1 some representative examples of the chemical structures
of these compounds are reported.
Quantitatively, the class of secoiridoids is the most represented in olive oil. These chemicals derive
from the cyclopentanopyran structural unit, known also as iridoid structure, after the breakage of the
ciclopentane ring. The main secoiridoids in olive oil are oleuropein and ligstroside, their aglycones result
constituted by elenolic acid esterified to hydroxytyrosol or tyrosol respectively [34]. Other secoiridoids,
derived from oleuropein and ligstroside, are oleacein and oleocanthal, the dialdehydic form of
decarboxymethyl elenolic acid bound to hydroxytyrosol or tyrosol respectively [34].
As a consequence of the oil production and aging processes, secoiridoids may easily hydrolyse
raising the level of free hydroxytyrosol and tyrosol in oils [45].
Polyphenols content is responsible for the taste of different olive oils: hydroxytyrosol determines
the bitter taste of olives and oils, while the stinging effect at pharynx level perceived after extra virgin
olive oil ingestion is due to oleocanthal, as described by Beauchamp et al., in 2005 [46] who also
demonstrated its ibuprofen-such as anti-inflammatory profile [46].
Many different studies tried to define the total phenolic content of olive oils. Of course this is a
very hard duty, since many factors such as cultivars, climate conditions, ripening stage of the olives,
but also olive oil production processes and storage affect olive phenolic content and composition [47].
Therefore, according to different studies, the amount of polyphenols in olive oil may range widely
from 200 to 1000 mg/kg [34,45,48].
Since hydroxytyrosol is the main phenolic compound present in olive oil, some authors analyzed
more than 250 extra virgin olive oil samples estimating that its median content is 137 mg/kg, while
the median content of oleocanthal is 85 mg/kg [44]. Other authors tried to calculate the daily
hydroxytyrosol intake concluding that it may not exceed 7 mg/day [42,45]. Globally, Dilis and
Trichopoulou reported a calculated daily intake of phenolic compounds of about 17 mg [49].
De La Torre estimated for a 25–50 mL olive oil intake/day a 9 mg polyphenol intake, where at
least 1 mg was due to hydroxytyrosol and tyrosol, and 8 mg represented by the oleuropein- and
ligstroside-aglycons [50].
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Olive Oil Phenols Bioavailability
After olive oi consumpt on its polyphenols are quickly metabolized and bsorbed. Through
the gastro intest nal tract, secoirid id agl c nes uch as oleuropein and ligstroside are mainly
hydrolyzed in elenolic acid plus hydroxytyrosol and tyrosol respectively [51]. Hydroxytyrosol and
tyrosol are absorbed in a dose-dependent manner [52,53], their peak plasma levels are found 1 h
after ingestion [53,54], while peak urine concentrations are detected 0–2 h after assumption [55,56].
However, when administered as aqueous solution their bioavailability is particularly low, highlighting
how the vehicle is important to determine hydroxytyrosol and tyrosol bioavailability [57].
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Once intravenously injected in rats, 14C labeled-hydroxytyrosol quickly disappeared from plasma
due to its fast metabolism and distribution to different tissues [58]. Hydroxytyrosol metabolism is
so fast that already 5 min after injection its metabolites are detectable in plasma, and its half-life has
been estimated between 1 and 2 min. Therefore, despite their good absorption, hydroxytyrosol and
tyrosol bioavailability result low due to the quick metabolism. Once absorbed, in fact, they undergo
an extensive first passage metabolism and phase I/II biotransformation at intestinal and liver
level. Ninety-eight percent of them are found in plasma and urine in a conjugated form, mainly
glucurono-conjugated or, in less extent, sulfated [56]. Considering this strong metabolism, some
authors proposed that hydroxytyrosol and tyrosol biological activity might be due to their metabolites.
Some data, in fact, suggest that hydroxytyrosol-3-O-glucuronide has got a stronger antioxidant activity
than hydroxytyrosol itself [59].
The blood brain barrier (BBB) has an extremely selective permeability. The aglycones of
polyphenols can cross membranes by a passive diffusion mechanism and therefore can be better
absorbed then their glycated counterparts [60].
Oleuropein aglycone can cross the BBB; in fact it has been detected in the rat brain parenchyma
after administration of a phenolic extract from olive cake [61].
Hydroxytyrosol 14C radioactivity measured in different tissues showed that it is distributed
to skeletal muscles, liver, heart, kidney, lung and brain, demonstrating that it can cross the
BBB [58], an essential feature to explain its neuroprotective role. Interestingly, hydroxytyrosol plasma
concentration does not only derive from olive oil polyphenols absorption, but also from dopamine
degradation. In fact, hydroxytyrosol is a by-product of dopamine oxidative metabolism, a pathway that
involves multiple enzymes, monoaminooxidase, aldehyde dehydrogenase and aldehyde reductase [50].
Oleocanthal bioavailability and its ability to cross the BBB have not yet fully established. It has
been reported that a significant amount of human urine metabolites following 50 mL olive oil ingestion
were from oleocanthal [62], providing evidence of the absorption and metabolism in the human body,
however further studies are necessary to fully understand the metabolism and bioavailability of
this compound.
4. Olive Oil Phenols and Oxidative Stress
Brain tissue, due to its high energy requirements, is characterized by high oxygen consumption
and metabolic rate. Moreover, cells of brain tissue present a very high polyunsaturated fatty
acid (PUFA) content and are known to have low antioxidant defenses. All together high oxygen
consumption, high PUFA content and low antioxidant defenses make brain prone to oxidative
stress [63–65]. Oxidative stress consists of a disequilibrium between free radical production and
scavenging that leads to an abnormal generation of reactive oxygen species (ROS) and oxidative
damage. It has been proposed and demonstrated that different neurodegenerative diseases share
oxidative stress as common characteristic [66,67].
Many physiological and pathological conditions are potential source of reactive oxygen species
(ROS) and are responsible for oxidative stress in brains affected by neurodegenerative diseases. Trace
elements such as copper, iron, aluminum, mercury and arsenic enhance free radical generation [68,69].
Neuroinflammation typically occurs during the development and progression of AD, PD and
other neurodegenerative diseases, and causes a strong increase of ROS level and induces oxidative
stress [70–73]. Formation of superoxide anion and production of hydrogen peroxide are triggered
by the induction of NADPH oxidase (NOX) subunit [74], this condition together with high nitric
oxide level, produced by the induction of inducible nitric oxide synthase (iNOS) [75], results in the
formation of peroxynitrite and nitrative stress [76]. Mitochondria are an additional potential site of
ROS production. Oxidative stress induced by impaired mitochondrial functions has been reported
in numerous neurodegenerative disorders such as multiple sclerosis (MS), PD, amyotrophic lateral
sclerosis (ALS) and AD [77–81].
Int. J. Mol. Sci. 2017, 18, 2230 5 of 27
To date many reports demonstrated that phenolics from Olea europaea L., found also in extra virgin
olive oil, exert strong antioxidant properties and are able to counteract oxidative stress in brain tissue.
Oleuropein and hydroxytyrosol act as direct free radical scavengers, hydroxytyrosol and oleocanthal
are strong cyclooxygenases (COX) inhibitors and oleuropein counteracts low density lipoprotein (LDL)
oxidations [46,82–85].
Early evidence showed that hydroxytyrosol counteracts Fe2+- and NO-induced loss of cellular
ATP and depolarization of mitochondrial membrane potential in murine dissociated brain cells [86].
More recently, long-term polyphenols-rich extra virgin olive oil dietary administration in mice
counteracted age-related dysfunctions in motor coordination and improved oxidative stress biomarkers
such as thiobarbituric acid reactive substances (TBARS) at cortex level. Moreover, it increases
glutathione peroxidase (GPx) activity in some brain regions such as cortex and cerebellum [29].
Recently, some authors evaluated oleuropein ability to counteract arsenic toxicity in mice. Arsenic
administered at 5 mg/kg/die through drinking water induces oxidative stress in multiple tissues such
as kidney, liver and brain as demonstrated by accumulation of oxidative damage biomarkers, protein
carbonyls, malondialdehyde (MDA) and depletion of antioxidant defenses and NO [87]. Oleuropein
treatment (30 mg/kg/die for 15 days) partially ameliorated arsenic-induced oxidative stress and NO
production [88]. Soni et al. [89] explored hydroxytyrosol protective effect on arsenic-induced oxidative
stress and mitochondrial dysfunction in rat brains and obtained similar results. They demonstrated
that hydroxytyrosol (10 mg/kg/die for 8 weeks) counteracted arsenic depletion of catalase (CAT),
manganese superoxide dismutase (MnSOD), and the reduction of mitochondrial complexes I, II,
IV activities, concluding that hydroxytyrosol might be considered a potential mitoprotective agent.
Olive oil administered to rats subjected to brain hypoxia–reoxygenation was demonstrated to exert
antioxidant and cytoprotective activity decreasing brain cell death, lipid peroxide level, counteracting
the decrease in glutathione levels and inhibiting prostaglandin E2 (PGE2) overproduction in brain
tissues [90].
Recently some evidence is arising showing that both hydroxytyrosol and oleuropein antioxidant
effects in the brain are mediated by the activation of the Keap1-Nrf2 pathway, which downstream
up-regulates cytoprotective enzymes such as thioredoxin reductase, heme oxygenase 1 (HO-1),
NAD(P)H:quinone oxidoreductase 1 (NQO1) and glutamate–cysteine ligase [91,92]. Moreover, even
though it acts also as direct scavenger, hydroxytyrosol neuroprotective activity vanish when Nrf2
is knocked down [91]. In fact, it has been demonstrated that intracellular phenolics concentrations
in neuronal cells is in the nanomolar-low micromolar range, not sufficient for a direct antioxidant
effect but high enough to activate a hormetic dose-response by modulating intracellular signaling
pathways [93].
5. Olive Oil Phenols in Counteracting Loss of Proteostasis
Many neurodegenerative diseases such as AD, PD, Lewy body dementia, Pick disease,
frontotemporal dementia, Huntington’s disease (HD), and ALS are associated with perturbed
proteostasis [94]. The proteostasis network includes different pathways related to protein synthesis,
folding, trafficking, secretion, and degradation distributed in different compartments inside the cell.
Dysfunctional proteins are safely degraded via the ubiquitin–proteasome system and the autophagy
pathway [95].
In recent years, the role of autophagy impairment in neurodegenerative disease has been
widely demonstrated [96,97]. Autophagy maintains cellular homeostasis through removal and
recycling of damaged macromolecules and organelles [98]. The autophagy pathway implies
sequestration of cytoplasmic components in double-membrane vesicles termed autophagosomes
that subsequently fuse with lysosomes to form autophagolysosomes [99]. Autophagy is triggered
by different stimuli: starvation, the presence of deposited materials and aged cellular organelles,
principally mitochondria (mitophagy) [100]. The delivery of cytoplasmic proteins to the lysosomes by
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autophagy can follow different pathways: CMA (chaperone-mediated autophagy), macroautophagy
and microautophagy [101].
Macroautophagy initiation is under the control of ULK1 that is negatively regulated by
mammalian target of rapamycin (mTOR) by phosphorylation [102]. Rigacci et al. [100] investigated
the molecular and cellular mechanisms of macroautophagy induction by oleuropein aglycone
using cultured neuroblastoma cells and an oleuropein aglycone fed mouse model of amyloid
beta (Aβ) deposition. Oleuropein aglycone induced autophagy in cultured cells through the
Ca2+-calmodulin-dependent kinase β-AMPK axis. The correlation between AMPK activation and
mTOR inhibition was demonstrated in the oleuropein aglycone-fed animal model in which decreased
phospho-mTOR immunoreactivity and phosphorylated mTOR substrate p70 S6K levels matched
enhanced phospho-AMPK levels, supporting the idea that autophagy activation by oleuropein
aglycone proceeds through mTOR inhibition.
A subsequent study evaluated the effect of picomolar doses of oleuropein on the modulation of
autophagy in nerve growth factor (NGF)-differentiated PC12 cells exposed to the potent parkinsonian
toxin 6-hydroxydopamine (6-OHDA) [103]. Interestingly, the results of this study were in contrast with
the results obtained by Rigacci et al., in fact oleuropein did not favor LC3-II accumulation and increased
the protein level of p62, an indicator of inhibition of autophagy, suggesting that picomolar doses
of oleuropein inhibit, rather than increase autophagy. In agreement with these results, the study of
Olivan et al. [104] investigated the protective effect of extra virgin olive oil nutritional supplementation
in an ALS mouse model. They observed that olive oil induced a significantly down-regulation of the
expression of LC3 and Beclin1 genes in muscles together with an increased survival rate, improved
motor coordination and reduced muscle damage.
In conclusion, the effect of oleuropein on autophagy depends on the dose as micromolar doses
increase autophagy, meanwhile picolomolar ones inhibit this degradative pathway. Of course further
studies should be carried out to better understand the role of nutritional doses of olive oil in the
modulation of the autophagic flux.
The proteasome, a nonlysosomal threonine protease, is a complex present in the cytoplasm of
cells [95] and responsible for the turnover of both normal and damaged intracellular proteins [105].
Most proteins degraded by proteasomes are tagged by polyubiquitination [106]. These proteins are then
conveyed into the core of the proteasome where they are degraded into short peptides by the internal
protease activities [101]. The impairment of the ubiquitin-proteasome system has been implicated in
the pathogenesis of a wide variety of neurodegenerative disorders [107] and its induction represents
an emerging therapeutic target to counteract these diseases. To our best knowledge, only one study
investigated the effect of oleuropein on the proteasome of human embryonic fibroblasts and showed
that this olive oil component is able to enhance proteasome activities in vitro stronger than other known
chemical activators, possibly through conformational changes of the proteasome [108]. In conclusion,
the effects of olive oil and olive oil components on autophagy are inconsistent, meanwhile the
modulation of the proteasome by olive oil has been investigated only on fibroblast suggesting that
these aspects should be further clarified.
6. Protective Effects of Olive Oil and Olive Oil Phenols against Acute Neurodegeneration
6.1. Ischemic Brain Injury
Stroke is a complex neurodegenerative disorder characterized by interruption of blood flow to
brain resulting in tissue hypoxia. Increasing evidence suggests that cerebral hypoxia and particularly
reperfusion are responsible for the release of excitatory amino acids, with subsequent receptor
activation leading to calcium influx, metabolic and electrophysiological dysfunction, lipid peroxidation
and oxidative stress [109]. As ischemic events are increased in elderly individuals [110], they are
particularly prone to the deleterious effects of these events. On these basis, the antioxidant and
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anti-inflammatory olive oil phenols have been considered as neuroprotective nutraceuticals to be used
in ischemic brain injury prevention and therapy.
The ability of virgin olive oil to counteract hypoxic brain damage was evaluated in a
hypoxia-reoxygenation in vitro model with fresh brain slices of rats receiving virgin olive oil for
30 days [90]. Virgin olive oil counteracted cell death by reducing lipid peroxidation, brain prostaglandin
E2, and NO production and by increasing glutathione concentration. In an attempt to better clarify the
contribution of olive oil phenols to the protection against hypoxia-reoxygenation, the same authors
investigated the possible neuroprotective effect of hydroxytyrosol and hydroxytyrosol acetate in
the same experimental model of hypoxia–reoxygenation [111]. Hydroxytyrosol and hydroxytyrosol
acetate inhibited LDH efflux in a concentration-dependent manner and interestingly, other well-known
antioxidants such as vitamin E and N-acetyl-cysteine, had no neuroprotective effect in this experimental
model suggesting that hydroxytyrosol and hydroxytyrosol acetate could have additional activities
besides the antioxidant one against hypoxia-reoxygenation.
Different in vivo studies evaluated the effect of virgin olive oil and its phenols in different
experimental model of ischemia/reperfusion in rodents.
Mohagheghi et al. [112] investigated the impact of dietary virgin olive oil on brain infarct
volume, brain edema, BBB permeability, and neurological dysfunction resulting from transient middle
cerebral artery occlusion (MCAO) in rats receiving 0.25–0.75 mL/kg virgin olive oil for 30 days.
The pretreatment with dietary virgin olive oil reduced infarct volume, brain edema, BBB permeability,
and neurobehavioral deficit scores. Another study investigated the protective effect of olive oil against
ischemia/reperfusion in mice. Mice were treated with olive oil for a week, then, ischemia was induced
by common carotid artery ligation and a week after ischemia the mice were post-treated with olive oil.
The treatment decreased cell death in the hippocampus CA1 suggesting a protective role of olive oil
against ischemia/reperfusion injury in this specific brain area. Moreover, Rabiei et al. [113] observed
that virgin olive oil administered to rats for 30 days influenced brain lipidomics during MCAO.
In particular, virgin olive oil increased brain phosphatidylcholine, cholesterol ester and cholesterol,
triglyceride, and cerebroside levels and decreased the brain ceramide levels indicating that the olive
oil could partly exert its effects via change in brain lipid levels.
In another study, the effects of tyrosol on infarct volume and sensory motor function deficit after
MCAO was investigated in rats [114]. Tyrosol showed a dose-dependent neuroprotective effect that
peaked at 64.9% in rats treated with 30 mg/kg of tyrosol. In rotarod, beam balance, and foot fault tests,
tyrosol exhibited protective effects against the sensory motor dysfunction.
Oleuropein treatment provides neuroprotective activity by decreasing cerebral infarct volume
and improving neurobehavioral functions after cerebral I/R injury in mice [115]. Moreover, oleuropein
showed an anti-apoptotic effect by increasing the ratio of Bcl-2/Bax through the up-regulation of the
expression of Bcl-2 and the down-regulation of the expression of Bax.
Of note, a study evaluating the association between the traditional MD and the incidence of
mortality from cerebrovascular disease (CBVD), showed that increased adherence to the MD was
inversely associated with CBVD incidence (adjusted hazard ratio = 0.85, 95% confidence interval: 0.74,
0.96) and mortality (adjusted hazard ratio = 0.88, 95% CI: 0.73, 1.06) [116]. These inverse trends were
mostly evident among women and with respect to ischemic rather than hemorrhagic CBVD and were
largely driven by consumption of vegetables, legumes, and olive oil.
6.2. Spinal Cord Injury
SCI is a highly debilitating pathology [117] which is caused initially by traumatic mechanical
injury (the primary injury) to the spinal cord that leads to the death of a number of neurons that
cannot be recovered and regenerated. Unfortunately, neurons continue to die for hours following the
trauma [118] and the outcome of SCI is closely related to the extent of the “secondary injury” mediated
by a series of cellular, molecular and biochemical cascades including calcium ion influx, oxidative
stress, inflammation, autoimmune response, vascular events, and apoptosis [119]. As the secondary
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injury appears to be susceptible to pharmacological interventions including the use of antioxidant
and anti-inflammatory agents, many studies have been focused on the modulation of the mechanisms
related to secondary injury.
Post-traumatic inflammation is characterized in part by the accumulation of neutrophils that
play an important role in the pathogenesis of secondary injury by the release of inflammatory
mediators [120]. Tissue myeloperoxidase (MPO) activity is a well-known biomarker of the extent of
post-straumatic neutrophil infiltration [121]. Focusing on this aspect, the anti-inflammatory effect of
oleuropein after spinal cord experimental injury was investigated in rats treated with a 20 mg/kg
single dose of oleuropein (i.p). immediately or 1 h after trauma [122]. Oleuropein strongly decreased
MPO activity, and interestingly the treatment at 1 h after the trauma was significantly more effective
that the other. In the same experimental conditions, oleuropein treatment was able to counteract
inflammation reducing the expression of tumor necrosis factor (TNF)-α, interleukin-1β (IL-1β), iNOS
and COX-2 [123] and lipid peroxidation, reducing MDA, increasing reduced glutathione (GSH)
level, attenuating myelin degradation in the dorsal funiculus, and counteracting apoptosis [124].
Impellizzeri et al. [123] investigated the effect of oleuropein aglycone, on the inflammatory response
in a mouse model of spinal cord trauma. Oleuropein aglycone was administered in mice 1 and 6 h
after trauma. The treatment with oleuropein aglycone significantly decreased histological damage,
motor recovery, nuclear factor kappa B (NF-κB) expression and inhibitor kappa B (IκB-α) degradation,
protein kinase A activity and expression, proinflammatory cytokines production such as TNF-α and
IL-1β, IL-6 inducible iNOS expression, neutrophil infiltration, lipid peroxidation, nitrotyrosine and
poly-ADP-ribose formation, glial cell-derived neurotrophic factor levels, and apoptosis.
In conclusion, both oleuropein and its aglycon form are promising agents in counteracting the
onset of inflammation and oxidative stress following SCI.
7. Protective Effects of Olive Oil Phenols against Chronic Neurodegeneration
7.1. Alzheimer’s Disease
AD is the most common form of dementia in the elderly that afflicts about 30 million
patients globally and is expected to increase enormously by 2050 [125]. Neuropathologically,
AD is characterized by increased accumulation of intracellular neurofibrillary tangles (NFTs) of
hyperphosphorylated tau protein and of extracellular Aβ protein deposits (Aβ plaques) derived from
amyloid precursor protein (APP) cleavage by γ-secretase and β-secretase [126–128]. There are two
different form of Alzheimer’s disease: the hereditary “familial” form is characterized by an early
onset (before age 50) associated with mutations in the APP gene and the genes for PS1 or PS2. On the
other hand, the second form of AD, known as sporadic or late-onset, affects the highest percentage of
the population [129]. Although Aβ plaques and NFTs are the main hallmarks of AD, mitochondrial
dysfunction, loss of calcium regulation, oxidative damage, and inflammation play an important role
in the onset and progression of AD [128,130–133]. Nowadays, there are no effective therapies for AD
and the only treatments available just alleviate disease symptoms. A large body of evidence supports
the beneficial effects of the MD in attenuating AD-like pathology, mild cognitive impairment and its
conversion to AD [130,134]. In particular, it has been suggested that olive oil phenolic components are
key factors in improving aging- and disease-associated behavioral deficits [21,135,136].
Extra-virgin olive oil rich in phenols (total phenol dose/day, 6 mg/kg) administered chronically
in the second half of mouse life span, improved contextual memory in the step-down test to levels
similar to young animals and prevented the age-related impairment in motor coordination in the
rotarod test [29]. This motor effect was correlated with reduced lipid peroxidation in the cerebellum.
Another study examined the effects of extra virgin olive oil on learning and memory in SAMP8 mice,
an age-related learning/memory impairment model associated with increased Aβ protein and brain
oxidative damage [137]. Mice receiving olive oil had improved acquisition in the T-maze and spent
more time with the novel object in one-trial novel object recognition versus mice which received
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coconut oil or butter. Moreover, olive oil increased brain glutathione levels suggesting reduced
oxidative stress as a possible protective mechanism. These effects, plus increased glutathione reductase
and SOD activity, and decreased tissue levels of 4-hydroxynoneal (4-HNE) and 3-nitrotyrosine were
enhanced by extra virgin olive oil enriched with phenols. A recent investigation explored the effect of
an extra virgin olive olive-enriched diet administered before or after the presence of Aβ deposit in
TgSwDI mice [137]. Animals fed with olive oil for 6 months and before the starting of Aβ accumulation
showed reduced Aβ and tau brain levels and a significant improvement in mouse cognitive behavior.
These effects were associated to an enhanced Aβ clearance pathways and reduced brain production of
Aβ via modulation of Aβ precursor protein processing. On the other hand, olive oil administrated after
Aβ accumulation starts, showed improved clearance across the BBB and significant reduction in Aβ
levels, but it did not affect tau levels or improved cognitive functions of TgSwDI mice suggesting that
the long-term consumption of olive oil starting at early age is more effective in protecting against AD.
A number of different studies investigated the effect of single olive oil phenols both in vitro
and in vivo. In vitro studies showed that oleuropein interferes with amyloid aggregation of amylin
and Aβ42 skipping the formation of toxic oligomeric species [32,138]. Using transgenic C. elegans
strains expressing Aβ42 as a simplified invertebrate model of AD, Diomede et al. [139] evidenced
that worms grown on oleuropein supplemented medium were protected against plaque deposits,
Aβ oligomer appearance. Moreover, worms did not evidence impairment of motility and displayed
increased survival. Dietary supplementation of oleuropein to TgCRND8 mice had a protective effect
by reducing de novo deposition of Aβ42 and promoting preformed plaque disassembly in the brain of
young/middle-aged animals [39].
Pyroglutamate-modified Aβ peptides at amino acid position three (pE3-Aβ) are receiving great
attention as possible key players in the pathogenesis of AD. pE3-Aβ is abundant in AD brain and
has a high aggregation propensity, stability and cellular toxicity. In aged mice displaying increased
pE3-Aβ in the brain deposits, oleuropein counteracted glutaminylcyclase-catalyzed pE3-Aβ production
by reducing enzyme expression and interfered with both Aβ42 and pE3-Aβ aggregation [39,140].
Interestingly, the beneficial effects of oleuropein were dose-related and a mix of olive phenols resulted in
quantitatively and qualitatively similar effects as those recorded with pure oleuropein [141], suggesting
that the observed effects are not closely related to oleuropein by itself. The same Authors demonstrated
that when Aβ42 is aggregated in the presence of oleuropein it is not toxic to neurons when injected into
the rat nucleus basalis magnocellularis, which is homologous to the nucleus of Meynert in humans, and
glia reactivity is reduced [142]. Oleuropein counteracted cognitive dysfunction induced by colchicine
in the hippocampal CA1 area in rats improving the retention performance of the spatial navigation task
in Morris water maze and attenuated colchicine induced oxidative stress reducing lipid peroxidation,
nitrite level, caspase 3 activity and increasing CAT and GPx activities [143].
The potential protective effect of tyrosol and hydroxytyrosol against Aβ-induced toxicity has
been investigated in cultured neuroblastoma N2a cells [144]. Both tyrosol and hydroxytyrosol
reduced cell death induced by Aβ, even if the treatment with both of them was not able to prevent
GSH decrease induced by H2O2 or Aβ. Interestingly, the presence of tyrosol and hydroxytyrosol
attenuated the nuclear translocation of the NF-κB subunit induced by Aβ exposure, suggesting
that these compounds act with an anti-inflammatory mechanism rather than an antioxidant one.
The effect of hydroxytyrosol was also explored in vivo feeding APP/PS1 transgenic mice, a familial
AD mouse model, with 5 mg/kg/day of hydroxytyrosol for 6 months [145]. Hydroxytyrosol did not
attenuate brain Aβ accumulation in AD mice even if improved EEG alteration, reduced inflammation
and mitochondrial oxidative stress by decreasing protein oxidation and the lipid peroxidation
product 4- HNE. In addition, hydroxytyrosol increased SOD2 expression and GSH levels, meanwhile
down-regulated HO-1 and NQO1 expression that were overexpressed in AD mice. It has recently
evidenced that diabetes is a risk factor for AD onset and development, being insulin resistance
the main link between diabetes and AD. In this context, Crespo et al. [146] demonstrated that
hydroxytyrosol exerts beneficial effects on insulin resistance associated with AD in an astrocytic model
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of AD. Pre- and post-treatment with hydroxytyrosol counteracted cell death induced by Aβ(25–35)
through the activation of Akt. In addition, hydroxytyrosol prevented the pronounced activation of
mTOR, thereby restoring proper insulin signaling.
Oleocanthal has been investigated for its anti-aggregation activities on tau protein. Tau is a
microtubule-associated protein that promotes microtubule assembly and stability. In Alzheimer’s
disease, tau aggregates into NFTs. In vitro, oleocanthal inhibits the polymerization of tau protein
through a covalent mechanism [147,148]. This aspect was first investigated by Li et al. [147] that
showed that oleocanthal forms an adduct with the lysine residue corresponding to K311 in tau protein,
which is a critical site for tau fibrillization, via initial Schiff base formation and thereby inhibiting
tau fibrillization. This study has some limitations as it was carried out using the fibrillogenic short
hexapeptide PHF6 which cannot be representative of a complex protein system and it is not fully
adequate to deduce the exact mechanism of action of oleocanthal. Monti et al. [148] demonstrated
that oleocanthal is capable of altering the fibrillization of tau protein reacting with the lysine ε-amino
groups of the tau fragment K18 in an unspecific fashion. Subsequently, the same authors investigated
the recognition process and the reaction profile between oleocanthal and the wild-type tau protein
demonstrating that oleocanthal interact with tau-441, inducing stable conformational modifications of
the protein secondary structure and also interfering with tau aggregation [149].
Pitt et al. [33] were the first to speculate that oleocanthal could alter Aβ aggregation states.
In particular, analysis of oligomers in the presence of oleocanthal showed an upward shift in molecular
weight and a decreased binding to synapses that was accompanied by significantly less synaptic
deterioration. Moreover, oleocanthal treatment improved antibody clearance of oligomers. These
results were further expanded by Abuznait et al. [38] that demonstrated both in cultured mice brain
endothelial cells and in C57BL/6 wild-type mice that oleocanthal enhances Aβ clearance from the
brain via up-regulation of P-glycoprotein (P-gp) and LDL receptor related protein-1 (LRP1), major Aβ
transport proteins at the BBB. In addition, the potential modifications in Aβ degradation induced by
oleocanthal were also studied by analyzing the levels of two enzymes implicated in the process: insulin
degrading enzyme and neprilysin. Interestingly, oleocanthal up-regulated both of them. As these
previous studies were not carried out using an AD model, the same research group investigated the
effect of oleocanthal on Aβ load in the brain parenchyma in TgSwDI mice, a well-known mouse model
of AD, and on Aβ deposit on brain microvessels. A 4-week treatment with oleocanthal reduced amyloid
load in the hippocampal parenchyma and microvessels. This reduction was associated with enhanced
cerebral clearance of Aβ across the BBB increasing the expression of P-gp and LRP1, and activation of
the apolipoprotein E (ApoE)-dependent amyloid clearance pathway in the mice brains by increasing
the expression of ATP-binding cassette transporter 1 (ABCA1), ApoE, and the nuclear receptors
PPARγ. Oleocanthal was also able to counteract inflammation in the brains reducing astrocytes
activation and IL-1β levels [31]. Very recently, the same experimental group showed that oleocanthal
attenuated the inflammation induced by Aβ oligomer in the human brain astrocytoma cell culture
CCF-STTG1 reducing the expression of IL-6 and glial fibrillary acidic protein (GFAP), and restoring
astrocyte neuro-supportive function by preventing Aβ oligomer down-regulation effects on glutamine
transporter (GLT1) and glucose transporter (GLUT1) [150]. Moreover, oleocanthal counteracted the
down regulation of the synaptic proteins GLT1 and PSD-95 induced by Aβ oligomer in SH-SY5Y cell
line transfected with APP695. On the basis of these results, the Authors suggested that the effect of
oleocanthal on neuronal cells could be direct and not mediated by astrocyte protective crosstalk.
As previously reported, oleocanthal has Ibuprofen-like activity thanks to its ability to inhibits
COX-1 and COX-2 [46] and this strong anti-inflammatory activity makes oleocanthal a promising
compound in counteracting AD-associated neuroinflammation.
Collectively these results (Figure 2) evidence that olive oil and its phenolic components play
a beneficial effect in AD via targeting multiple pathological aspects of this disease and confirm the
hypothesis that olive oil consumption is strongly associated with the positive effect showed by MD on
AD risk. [134,151]
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7.2. Parkinson’s Disease
Parkinson’s disease is characterized by the progressive loss of dopaminergic neurons in the
midbrain region known as substantia nigra pars compacta and by the presence of cytoplasmic protein
aggregates, called Lewy body, and Lewy neurites in remaining neurons [152,153]. Although the precise
etiology of PD remains unknown, it is becoming increasingly clear that the onset of PD is multi-factorial
and involves disruptions in multiple cellular systems. In particular, the loss of dopaminergic neurons
has been associated to different causes including mitochondrial dysfunction, oxidative stress, loss of
glutathione, neuroinflammation, loss of neurotrophic factor signaling, abnormal protein accumulation,
and environmental toxins [154–156]. The highest number of PD cases are sporadic [157,158], and only
10% are of genetic origin [159], mainly linked to mutations in α-synuclein protein [160], a principal
component of Lewy body inclusions [161], parkin [159,162], PTEN-induced putative kinase 1 (PINK1),
dardarin, and protein deglycase (DJ-1) [163].
Dopaminergic neurons are highly prone to oxidative stress as dopamine itself can spontaneously
undergo auto-oxidation leading to the production of toxic molecules such as hydrogen peroxide,
superoxide radicals and dopamine (DA)-quinone species [47,164]. Oxidized DA can reacts with
sulfhydryl groups in cysteinyl proteins to form Michael adduct and generates ROS through redox
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cycling [165–167]. In addition, mitochondrial dysfunction and neuroinflammation seems to play a
fundamental role in increasing ROS level in the substantia nigra of PD patients [168].
Current therapies for PD are not able to prevent dopaminergic neuron loss or stop the progression
of the disease, only delay the onset or reduce the motor symptoms. The gold standard therapy
against PD relies on restoring the optimum level of DA and its associated signaling pathways by
the administration of L-3,4-dihydroxyphenylalanine (L-DOPA), a precursor of DA [169]. Another
strategy for PD therapy is the use of monoamine oxidase (MAO)-B inhibitors in order to stop DA
degradation [170]. Both of these therapeutic approach have important side effects and, in this milieu,
different strategies are being under investigation [171]. Among them, nutraceutical approaches
involving natural compounds present in common food such as olive oil has been shown to impart
beneficial effect in PD [17,172–175].
To our knowledge, no studies have been carried out to explore the effect of olive oil in
counteracting Parkinson’s disease, on the other hand, many studies have investigated the role of single
olive oil phenols in modulating the cellular system alteration involved in the onset of the disease.
Dewapriya et al. [176] examined the protective effect of tyrosol against the parkinsonian
toxin1-methyl-4-phenylpyridinium (MPP+) in dopaminergic CATH.a neurons. MPP+ selectively
enters into DA-producing neurons and inhibits the mitochondrial electron transporter chain leading
to oxidative stress, which ultimately causes neuronal death [177]. Tyrosol attenuated mitochondrial
dysfunction and intracellular ATP depletion induced by MPP+. Moreover, tyrosol up-regulated the
expression of the antioxidant enzymes SOD-1 and SOD-2 and DJ-1 and increased the activation of Akt,
suggesting that tyrosol, in this specific experimental conditions, achieved neuroprotection probably
via an Akt-signaling-pathway-dependent mechanism.
In another in vitro model of Parkinson’s disease, oleuropein (20 and 25 µg/mL) decreased cell
damage and reduced oxidative stress and apoptosis induced by 6-OHDA in PC12 cells [178]. This data
were further confirmed by a recent study evaluating the neuroprotective effect of picomolar doses of
oleuropein in PC12 cells exposed to 6-OHDA [103]. In particular, oleuropein lowered 6-OHDA-induced
apoptosis, as established by assessing levels of specific DNA denaturation by formamide, as well as the
ratio of pro-apoptotic Bax and anti-apoptotic Bcl-2 expression, and reduced mitochondrial superoxide
anion levels.
The protective effects of hydroxytyrosol against toxins commonly used in PD research, including
DA, 6-OHD, and MPP+ were evaluated on dopaminergic SH-SY5Y cells [179]. Hydroxytyrosol had a
strong protective effect against DA- or 6-OHDA-induce cell death, but had little effect on MPP+-induced
cytotoxicity suggesting that the cellular mechanisms underlying DA- or 6-OHDA-induced toxicity are
different from that of MPP+. Moreover, 20 µM hydroxytyrosol induced phase II detoxifying enzymes
such as NQO1, HO-1, glutathione S-transferase and the modifier subunit of glutamate cysteine ligase
which catalyzes the first and rate-limiting step in the synthesis of GSH. Using an NQO1 inhibitor, the
authors revealed that increased NQO1 expression contributed to the protective effect of hydroxytyrosol
against dopaminergic cell death.
MAO-B inhibitors are used in the symptomatic treatment of Parkinson’s disease as they
increase synaptic dopamine by blocking its degradation [170]. On the other hand, the rise in
cytoplasmic dopamine leads to an increase of spontaneous oxidation to DA-quinone species,
including 5-S-cysteinyl-dopamine (Cys-DA) [170,180], superoxide radicals and hydrogen peroxide [47].
With the purpose to mitigate the MAO inhibitor-induced increase in spontaneous DA oxidation,
Goldstein et al. [181] investigated the effect of hydroxytyrosol on PC12 cells in the presence of different
MAO inhibitors: clorgyline or the MAO-B inhibitors rasagiline or selegiline. The results clearly
showed that hydroxytyrosol decreased Cys-DA levels induced by MAO inhibitors, suggesting that
this olive oil phenol could be used to enhance the efficacy of the clinical treatment of Parkinson’s
disease. Vauzour et al. [182] showed that tyrosol counteracted cell death induced by Cys-DA in
primary cultures of mouse cortical neurons. Of note, they demonstrated that the protection evoked
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by tyrosol was equal to or greater than that observed for the flavonoids, (+)-catechin, (−)-epicatechin
and quercetin.
Levodopa, the gold standard in the treatment of Parkinson’s disease, can be converted to DA
in the periphery by catechol-O-methyl transferase (COMT), reducing the level of levodopa reaching
the brain. For this reason, COMT inhibitors are used as adjuncts to levodopa therapy in Parkinson’s
disease. In this context, Gallardo et al., investigated the inhibition of COMT activity by hydroxytyrosol,
measuring intracellular dopamine and its metabolite levels in the corpus striatum of rats [156].
The animals received a single dose of 20 mg/kg or one daily dose of 20 mg/kg for 5 days of
hydroxytyrosol. Both treatments produced a significant increase in the intracellular levels of DA
and its metabolite, 3,4-dihydroxyphenylacetic acid, with the chronic treatment most effective that the
acute one.
Summarizing, in the context of Parkinson’s disease olive oil phenols are multitarget compounds
able to modulate different cellular mechanism involved in the onset and progression of the disease.
Most of the studies have been carried out in cell cultures, so further in vivo studies are absolutely
needed to confirm the protective effects of olive oil phenols observed in vitro. Moreover, in our opinion,
it would be important to explore the protective effect of olive oil as a whole in Parkinson’s disease.
7.3. Multiple Sclerosis
MS is a chronic inflammatory and neurodegenerative disease of the central nervous system
characterized by focal lesions of inflammation, BBB breakdown, axonal and oligodendrocyte injury,
gliosis, and demyelination [183,184]. The incidence of MS has increased from 2.1 million in 2008
to 2.3 million in 2013 [185] and is now the first cause of disability after traumatic brain injury
in young individuals [186]. In the pathogenesis of MS different parts of the immune system are
involved including autoreactive T cells, macrophages and microglial cells, as well as antibodies and
inflammation-related enzymes such as COX-2 and iNOS and cytokines such as IFN-γ, TNF-α or
IL-1 [187]. Moreover, increasing evidence suggests that, due to the excessive generation of ROS,
oxidative stress is one of the most important components involved in the pathogenesis of this
disease [188,189]. Likewise other important neurodegenerative diseases, nowadays no definitive
therapy are available for MS and conventional therapeutic approaches are related to many undesirable
side effects [190].
It has been shown that the up-regulation of matrix metallopeptidase 9 (MMP-9) increases the
permeability of BBB, facilitates the infiltration of leukocytes into the central nervous system, and leads
to myelin degradation as well as neuronal damage in multiple sclerosis patients [191,192]. In this
context, Liuzzi et al. [193] investigated the effect of an olive oil extract on the levels of MMP-9 and
MMP-2 in rat astrocytes stimulated with LPS and in serum samples from multiple sclerosis patients.
The results demonstrated that olive oil extract was able to reduce mRNA levels and activity of MMP-9
and MMP-2 enzymes both in activated astrocytes and serum of multiple sclerosis patients, suggesting
that olive oil might be useful in inhibiting the activity of gelatinases involved in the course of the
inflammatory responses observed in MS.
To our knowledge no other studies have been carried out to investigate the effect of olive oil
phenols in counteracting multiple sclerosis. Of note, two different studies explored the protective
effects of two natural triterpenes present in olive oil, oleanolic acid and erythrodiol on experimental
autoimmune encephalomyelitis (EAE) that is considered the best available model for understanding
events in multiple sclerosis [194,195]. The prophylactic administration of triterpenes delayed the
onset and decreased the severity of the disease ameliorating the neurological signs of EAE-mice,
by preventing up-regulation of specific antibodies and inflammatory cytokines, and stabilizing the
BBB integrity, thus reducing the migration of leukocytes in the central nervous system (CNS).
Overall, olive oil consumption in the frame of the MD to ameliorate the wellness of MS patients is
strongly suggested [196].
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7.4. Amyotrophic Lateral Sclerosis
ALS is an adult-onset, progressive, and untreatable neurological disease characterized by selective
loss of motor neurons in brain and spinal cord muscle weakness, which results in atrophy and spasticity,
typically leading to paralysis and finally death because the respiratory muscles are compromised [197].
Although most cases of ALS are sporadic and of unknown etiology, less than 10% of patients
have familial ALS, typically as an autosomal dominant trait [198]. The two forms of ALS are clinically
indistinguishable, even if 15–20% of familial ALS patients carry mutations in the gene encoding for the
antioxidant enzyme Cu/Zn SOD-1 [199,200]. The role of SOD-1 in ALS is not completely understood,
but it has been suggested that the neurodegenerative disorder is due to gain of toxic function rather
than loss of SOD1 enzymatic activity [201,202].
The mechanism of motor neuron degeneration is under intense investigation. There is increasing
evidence that protein misfolding, mitochondrial dysfunction, oxidative radical damage, defective
axonal transport, excitotoxicity, insufficient growth factor signaling and inflammation are responsible
for the etiology of ALS [203,204]. ALS treatments is only palliative, and no drugs are available to halt the
progression of the disease [205]. In this context, Oliván et al. [104] observed that olive oil ameliorated
pathological outcomes and delayed the disease onset in an ALS model of mice overexpressing a
mutant form of SOD-1 (SOD1G93A variant). Mice that received olive oil survived longer and showed
better motor performance and larger muscle fiber area than animals receiving palm oil. In addition,
olive oil supplementation improved the muscle status as demonstrated by the increased expression of
myogenic factors (Myod1 and Myog) and autophagy markers (LC3 and Beclin1), as well as diminished
endoplasmic reticulum stress through decreasing Atf6 and Grp78. Another study [206] investigated
the effect of a phenolic extract obtained from a commercial Italian olive oil in modulating TLR4
signaling that has been reported to be involved in ALS pathogenic mechanisms [207]. The results
proved that olive oil phenolic extract induced a complete inhibition of TLR4 activation, prevented
the death of motoneurons induced by LPS and in motoneurons/glia co-cultures was very effective in
protecting motoneurons from the toxicity of microglia carrying the SOD1G93A mutation. Olive oil
phenols were also able to inhibit the release of nitric oxide induced by LPS treatment or SOD1mut
glia, suggesting that olive oil phenols could have neuroprotective effects related to the modulation of
inflammatory mediators.
8. Clinical Trials and Population Studies on Olive Oil and Its Phenols
Few clinical trials and population studies have been carried out to investigate the effects of olive
oil and its phenols in counteracting neurodegeneration and most of them are related to the MD and its
impact on cognitive decline. The “Three-City-Study” was the first to evidence an association between
olive oil consumption and cognitive decline. The study was carried out on 8028 subjects aged 65 years
and over recruited from three French cities. Participants with moderate or intensive use of olive oil
compared to those who never used olive oil showed lower odds of cognitive deficit for verbal fluency
and visual memory [208].
The PREDIMED-NAVARRA randomized trial assessed the effect on cognition of a nutritional
intervention using a MD supplemented with extra-virgin olive oil in comparison with a low-fat control
diet on 522 participants at high vascular risk. After 6.5 years of intervention the participants allocated
to the MD plus extra virgin olive oil showed higher mean Mini-Mental State Examination and Clock
Drawing Test scores with significant differences versus control, suggesting a protective effect of olive
oil against age-related cognitive impairment [209]. A clinical trial aimed to evaluate the effect of
vegetal oil on cognitive impairment in respect to olive oil as a placebo (ClinicalTrials.gov Identifier:
NCT02778581 study start date March 2016) is now recruiting. The results will help to clarify if olive oil
has a higher effect in improving cognition compared to other vegetable oils.
In this context, more clinical studies are needed to understand the exact contribution of olive oil
to the beneficial effect of the MD and, in particular, to elucidate the protective effect of olive oil and its
phenols on neurological disorders.
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9. Conclusions
The beneficial effects of olive oil and its phenolics on neurological disorders have been extensively
investigated and associated to the modulation of many different cell pathways. Among phenolics,
oleocanthal, oleuropein, hydroxytyrosol and tyrosol have been mostly explored (Table 1 summarizes
their effects against neurodegeneration). They possess a direct antioxidant activity in vitro, although
their low concentration in vivo is not sufficient to justify a protective mechanism related to their ability
to scavenge ROS. Evidence is arising suggesting that olive oil phenol effects in the brain could be
mediated by the activation of the Keap1-Nrf2 pathway, a key regulator of the antioxidant system.
Regarding acute brain injury, olive oil and its phenols have been shown to counteract stroke and spinal
cord injury. In particular, olive oil, hydroxytyrosol, tyrosol and oleuropein demonstrated to reduce
infarct volume, apoptosis and ameliorate the outcome of these injuries. Only oleuropein has been
investigated in relation to spinal cord injury and its protective effect has been ascribed to its ability to
reduce inflammation.
Concerning chronic neurodegeneration, the effect of olive oil and its phenolic compounds
have been mainly investigated in relation to AD and PD. Olive oil phenols reduce both Aβ and
neurofibrillary tangles deposition interfering at different levels with their production and clearance.
Moreover, their ability to boost the antioxidant system and reduce inflammation has also been
associated with their protective effect in AD, PD, MS, and ALS.
To conclude, olive oil phenols, thanks to their multiple modes of action, have a great potential for
therapeutic success in counteracting multifactorial pathologies such as neurological disorders. In this
regard, further clinical trials are needed to provide a broader insight on the preventive/therapeutic
potential and to identify biologically relevant concentrations.
Table 1. Studies showing a protective activity of olive oil phenols against neurological disorders.
Olive Oil Phenols Activity References
Oleuropein
Counteraction of LDL oxidations [85]
Counteraction of oxidative stress at brain level [88,91]
Induction of autophagy at micromolar concentration [100]
Inhibition of autophagy at picomolar concentration [103,104]
Reduction of cerebral infarct volume after cerebral ischemia/reperfusion injury in mice [115]
Reduction of inflammatory biomarkers (TNF-α, IL-1α, iNOS, COX-2) after spinal cord
injury (animal model) [122–124]
interference with amyloid aggregation (in vitro) [32,138]
Reduction of Aβ42 deposition and plaque deposit (animal models) [3,139]
Counteraction of pE3-Aβ production [39,140]
Reduction of oxidative stress and apoptosis induced by 6-OHDA (in vitro) [103,178]
Oleocanthal
Inhibition of COX activity [46]
Anti-aggregation activities on tau protein (in vitro) [147–149]
Enhancement of Aβ clearance from the brain (animal model) [38]
Reduction of astrocytes activation and IL-1β levels in AD model [31,150]
Hydroxytyrosol
Inhibition of COX activity [84]
Counteraction of oxidative stress at brain level [86,91]
Counteraction of hypoxic brain damage (ex-vivo model) [111]
Attenuates Aβ induced inflammation (animal model) [145]
Beneficial effects on insulin resistance associated with AD [146]
Protection against DA- or 6-OHDA-induce cell death (in vitro) [179]
Inhibition of COMT activity, leading to increased intracellular DA levels (animal model) [156]
Tyrosol
Counteraction of hypoxic brain damage [111]
Attenuation of mitochondrial dysfunction and ATP depletion induced by MPP+ (in vitro) [177]
Counteraction of Cys-DA induced cytotoxicity (in vitro) [182]
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ABCA1 ATP-binding cassette transporter 1
AD Alzheimer’s disease
ALS amyotrophic lateral sclerosis
APOE apolipoprotein E
APP amyloid precursor protein
Aβ amyloid-β
BBB blood brain barrier
CAT catalase
CBVD cerebrovascular disease







GFAP glial fibrillary acidic protein
GLT1 glutamine transporter 1




HO-1 heme oxygenase 1
IL-1β interleukin-1β
iNOS inducible nitric oxide synthase
Keap1 Kelch-like-ECH-associated protein 1
LC3 protein 1 light chain 3
L-DOPA L-3,4-dihydroxyphenylalanine
LRP1 LDL receptor related protein-1
MAO monoamine oxidase
MCAO middle cerebral artery occlusion
MD Mediterranean diet
MDA Malondialdehyde




mTOR mammalian target of rapamycin
NF nuclear factor
NFTs neurofibrillary tangles
NGF nerve growth factor
NGF nerve growth factor
NO nitric oxide
NQO1 NADPH quinone oxidoreductase 1
Nrf2 nuclear factor NF-E2-related factor 2
PD Parkinson’s disease
pE3-Aβ pyroglutamate-modified Aβ peptides at amino acid position three
PGE2 prostaglandin E2
P-gp P-glycoprotein
PINK1 PTEN-induced putative kinase 1
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PPARγ peroxisome proliferator–activated receptor gamma
PS1 presenilin-1
PS2 presenilin-2
PSD-95 postsynaptic density protein 95
PUFA polyunsaturated fatty acid
ROS reactive oxygen species
SCI spinal cord injury
SOD superoxide dismutase
TBARS thiobarbituric Acid Reactive Substances
TNF tumor necrosis factor
ULK1 unc-51-like kinase 1
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